<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02169115</url>
  </required_header>
  <id_info>
    <org_study_id>CIGE025EDE17T</org_study_id>
    <secondary_id>2011-005615-87</secondary_id>
    <nct_id>NCT02169115</nct_id>
  </id_info>
  <brief_title>Urticaria Facticia Treatment With Omalizumab (UFO)</brief_title>
  <acronym>UFO</acronym>
  <official_title>Double-blind, Placebo-controlled 12-week, Parallel-group Study With a 6 Weeks Follow up Period to Demonstrate Efficacy and Safety of Subcutaneous Omalizumab in Patients With Urticaria Factitia Refractory to Standard Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Urticaria is a very frequent skin condition characterized by transient wheal and flare type
      skin reactions associated with severe pruritus. In Europe alone, more than 5 million patients
      are thought to suffer from persisting urticaria symptoms, which either occur spontaneously,
      i.e. in chronic spontaneous urticaria (CSU), or as a result of environmental physical stimuli
      such as friction, pressure, UV irradiation or cold (physical urticaria). Urticaria factitia
      (also known as dermographic urticaria and symptomatic dermographism) is characterized by
      whealing and itching following a minor stroking pressure, rubbing or scratching of the skin.
      The majority of patients with urticaria factitia benefits from treatment with nonsedating
      antihistamines. Some patients, however, do not achieve adequate symptom control even with
      updosing of antihistamines and may suffer from substantial quality of life impairment . Since
      even very minor stroking of the skin can lead to the development of wheals and severe
      itching, these patients are for example limited in their choice of clothing and are impaired
      in their social interaction and partnership.

      In all patients with a history of wheals after stroking of the skin, a provocation test
      should be performed. This can be done by stroking of the skin lightly with a smooth blunt
      object (e.g. the tip of a closed ball point pen or a wooden spatula) or a purpose-built
      instrument, known as a dermographometer. For the diagnosis of symptomatic dermographism, the
      smooth blunt object should be held perpendicular to the skin and should be used to apply a
      light stroking pressure to the skin of the upper back or volar forearm. The reaction is
      considered positive in patients who show a weal response and report pruritus at the site of
      provocation.

      Patients with a positive test reaction should be evaluated for individual pressure
      thresholds. For this purpose a provocation device (FricTest) has been developed that allows
      for reproducible and standardized threshold testing. Threshold testing enables physicians to
      assess disease severity and treatment response more precisely.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Provocation Thresholds From Baseline to Day 70 in Urticaria Factitia Patients After Treatment With Omalizumab Compared to Placebo</measure>
    <time_frame>70 days</time_frame>
    <description>Patients receive provocation test by FricTest (standardized stroking of the skin). FricTest ratings are from 0 (no wheal development to the longest pin) to 4 (wheal development to all four pins). The development of wheals within 30 minutes after provocation is monitored.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Assess the Effects of Omalizumab in Urticaria Factitia Patients on Quality of Life</measure>
    <time_frame>70 days</time_frame>
    <description>Change in quality of life scores assessed by Dermatology Life Quality Index (DLQI) and UF specific life quality questions from baseline to day 70 after treatment with omalizumab compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Assess the Effects of Omalizumab in UF Patients on Number of Symptom Free Days</measure>
    <time_frame>70 days</time_frame>
    <description>Change in number of symptom free days as assessed by a patient diary from baseline to day 70 after treatment with omalizumab compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Assess the Effects of Omalizumab in UF Patients on Physician Global Assessment of Disease Severity</measure>
    <time_frame>70 days</time_frame>
    <description>Change in physician global assessment of disease severity assessed by visual analogue scale by a physician from baseline to day 70 after treatment with omalizumab compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Assess the Effects of Omalizumab in UF Patients on Patient Global Assessment of Disease Severity</measure>
    <time_frame>70 days</time_frame>
    <description>Change in patient global assessment of disease severity assessed by visual analogue scale by the patient from baseline to day 70 after treatment with omalizumab compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Assess Long-term Effects of Omalizumab in UF Patients</measure>
    <time_frame>112 days</time_frame>
    <description>To assess long-term effects of omalizumab in UF patients, change in friction thresholds from day 70 (week 10) to day 112 (week 16) will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Assess the Safety of Omalizumab in UF Patients</measure>
    <time_frame>112 days</time_frame>
    <description>Safety of patients treated with omalizumab: This includes physical examination, routine safety laboratory assessments, vital signs and adverse event reporting</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Symptomatic Dermographism</condition>
  <arm_group>
    <arm_group_label>Omalizumab 150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Omalizumab 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omalizumab</intervention_name>
    <description>150mg, s.c., every 4 weeks</description>
    <arm_group_label>Omalizumab 150mg</arm_group_label>
    <other_name>Xolair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omalizumab</intervention_name>
    <description>300mg, s.c., every 4 weeks</description>
    <arm_group_label>Omalizumab 300mg</arm_group_label>
    <other_name>Xolair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, s.c., every 4 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (18-75 years)

          -  Informed consent signed and dated

          -  Able to read, understand and willing to sign the informed consent form and abide with
             study procedures

          -  Diagnosis of UF lasting for at least 6 months

          -  Willing, committed and able to return for all clinic visits and complete all
             study-related procedures, including willingness to have SC injections administered by
             a qualified person

          -  In females of childbearing potential: Negative pregnancy test; females willing to use
             highly effective contraception (Pearl-Index &lt; 1). A woman will be considered not of
             childbearing potential if she is post-menopausal for greater than two years or
             surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy)

          -  No participation in other clinical trials 4 weeks before and after participation in
             this study

        Exclusion Criteria:

          -  Patients with acute urticaria

          -  Concurrent/ongoing treatment with immunosuppressives (e.g. systemic steroids,
             cyclosporine, methotrexate, dapsone or others) within 4 weeks or 5 half lives prior to
             day 0, whichever is longer

          -  Significant medical condition rendering the patient immunocompromised or not suitable
             for a clinical trial

          -  Significant concomitant illness that would adversely affect the subject's
             participation or evaluation in this study

          -  History of malignancies within five years prior to screening other than a successfully
             treated non-metastatic cutaneous, basal, or squamous cell carcinoma and/or in situ
             cancer

          -  Presence of clinically significant laboratory abnormalities

          -  Lactating females or pregnant females

          -  Subjects for whom there is concern about compliance with the protocol procedures

          -  Any medical condition which, in the opinion of the Investigator, would interfere with
             participation in the study or place the subject at risk

          -  History of substance abuse (drug or alcohol) or any other factor (e.g., serious
             psychiatric condition) within the last 5 years that could limit the subject's ability
             to comply with study procedures

          -  Subjects who are detained officially or legally to an official institute

          -  Previous use of omalizumab within the last 6 months

          -  Intake of antihistamines or leukotriene antagonists within 4 days prior to visit 1

          -  Intake of oral corticosteroids within 14 days prior to visit 1

          -  Use of depot corticosteroids or chronic systemic corticosteroids within 21 days before
             beginning of the study

          -  Known hypersensitivity to any ingredients, including excipients (sucrose, histidine,
             polysorbate 20) of the study medication or drugs related to omalizumab (e.g.:
             monoclonal antibodies, polyclonal gammaglobulin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Metz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Dermatology Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology University Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2014</study_first_submitted>
  <study_first_submitted_qc>June 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2014</study_first_posted>
  <results_first_submitted>October 28, 2015</results_first_submitted>
  <results_first_submitted_qc>December 11, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 18, 2016</results_first_posted>
  <last_update_submitted>November 2, 2016</last_update_submitted>
  <last_update_submitted_qc>November 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Martin Metz</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Omalizumab 150mg</title>
          <description>Omalizumab: 150mg, s.c., every 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Omalizumab 300mg</title>
          <description>Omalizumab: 300mg, s.c., every 4 weeks</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo: Placebo, s.c., every 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Omalizumab 150mg</title>
          <description>Omalizumab: 150mg, s.c., every 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Omalizumab 300mg</title>
          <description>Omalizumab: 300mg, s.c., every 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo: Placebo, s.c., every 4 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Provocation Thresholds From Baseline to Day 70 in Urticaria Factitia Patients After Treatment With Omalizumab Compared to Placebo</title>
        <description>Patients receive provocation test by FricTest (standardized stroking of the skin). FricTest ratings are from 0 (no wheal development to the longest pin) to 4 (wheal development to all four pins). The development of wheals within 30 minutes after provocation is monitored.</description>
        <time_frame>70 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omalizumab 150mg</title>
            <description>Omalizumab: 150mg, s.c., every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Omalizumab 300mg</title>
            <description>Omalizumab: 300mg, s.c., every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Placebo, s.c., every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Provocation Thresholds From Baseline to Day 70 in Urticaria Factitia Patients After Treatment With Omalizumab Compared to Placebo</title>
          <description>Patients receive provocation test by FricTest (standardized stroking of the skin). FricTest ratings are from 0 (no wheal development to the longest pin) to 4 (wheal development to all four pins). The development of wheals within 30 minutes after provocation is monitored.</description>
          <units>wheal development up to four pins</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="1.7"/>
                    <measurement group_id="O2" value="-2.0" spread="1.8"/>
                    <measurement group_id="O3" value="-0.6" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.8</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.7</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.0</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.8</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.6</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.4</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess the Effects of Omalizumab in Urticaria Factitia Patients on Quality of Life</title>
        <description>Change in quality of life scores assessed by Dermatology Life Quality Index (DLQI) and UF specific life quality questions from baseline to day 70 after treatment with omalizumab compared to placebo.</description>
        <time_frame>70 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess the Effects of Omalizumab in UF Patients on Number of Symptom Free Days</title>
        <description>Change in number of symptom free days as assessed by a patient diary from baseline to day 70 after treatment with omalizumab compared to placebo</description>
        <time_frame>70 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess the Effects of Omalizumab in UF Patients on Physician Global Assessment of Disease Severity</title>
        <description>Change in physician global assessment of disease severity assessed by visual analogue scale by a physician from baseline to day 70 after treatment with omalizumab compared to placebo.</description>
        <time_frame>70 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess the Effects of Omalizumab in UF Patients on Patient Global Assessment of Disease Severity</title>
        <description>Change in patient global assessment of disease severity assessed by visual analogue scale by the patient from baseline to day 70 after treatment with omalizumab compared to placebo.</description>
        <time_frame>70 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess Long-term Effects of Omalizumab in UF Patients</title>
        <description>To assess long-term effects of omalizumab in UF patients, change in friction thresholds from day 70 (week 10) to day 112 (week 16) will be assessed</description>
        <time_frame>112 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess the Safety of Omalizumab in UF Patients</title>
        <description>Safety of patients treated with omalizumab: This includes physical examination, routine safety laboratory assessments, vital signs and adverse event reporting</description>
        <time_frame>112 days</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Omalizumab 150mg</title>
          <description>Omalizumab: 150mg, s.c., every 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Omalizumab 300mg</title>
          <description>Omalizumab: 300mg, s.c., every 4 weeks</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo: Placebo, s.c., every 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Unspecified renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Acute cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Martin Metz</name_or_title>
      <organization>Charité- Dpt. of Dermatology and Allergy</organization>
      <phone>+49 30 450 518 159</phone>
      <email>martin.metz@charite.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

